Sentrimed, Inc.
Biotechnology · MULLICA HILL, NJ
BiotechnologySEC Form D
Sentrimed, Inc. filed a Form D with the U.S. Securities and Exchange Commission on May 13, 2026, reporting $250,000 raised toward a $1,000,000 offering.
Incorporated in Delaware and based in MULLICA HILL, NJ, it operates in the Biotechnology sector.
Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that Sentrimed, Inc. has raised capital from private investors.
Browse more recently funded companies in Biotechnology.
Executives & Directors
- William RagatzExecutive Officer · Director
- Bradley GalerDirector
- Jack GoldbergExecutive Officer · Director
- Mari Rhodehamel YinExecutive Officer · Director
- Gary GoldbergExecutive Officer
- Arye RosenExecutive Officer
- Christopher LeonardExecutive Officer
- Tabbetha DobbinsDirector
Recently funded in Biotechnology
Other companies that recently filed a Form D
$3.2MRaised
Goldenrod Therapeutics, Inc.
$10.0MRaised
Human Biotech, Inc.
$1.0MRaised
Optimeos Life Sciences, Inc.
$2.5MRaised
BioStem Technologies, Inc.
$1.6MRaised